Krystal Biotech Q2 net income rises 43% to $54.8 million; revenue climbs 24% to $119.2 million
Reuters2026/08/03 11:05- Krystal Biotech posted 2Q net income of $54.8 million, or $1.79 per diluted share, up from $38.3 million a year earlier.
- Product revenue rose 24% year over year to $119.2 million, with gross margin at 95%.
- Cash and investments totaled $1.1 billion at quarter-end; FY 2026 non-GAAP R&D and SG&A expense guidance was $175 million-$195 million.
- VYJUVEK logged $965.9 million in global revenue since launch, with more than 730 reimbursement approvals and over 640 unique U.S. prescribers.
- Management flagged multiple clinical readouts in 2H 2026; VYJUVEK launches in Spain and Italy remain targeted before year-end.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Delta Electronics (Thailand)'s Recent Selloff Presents Accumulation Opportunity -- Market Talk
The data center construction boom may increase inflationary pressure, and the Reserve Bank of Australia may be forced to maintain high interest rates.
The data center construction boom in Australia may lead to demand exceeding the supply capacity of the economy, which could push up inflation and force the Reserve Bank of Australia to maintain higher interest rates.
Reliance step-down unit Roptonal dissolves in Cyprus with effect Aug. 18, 2026
Crypto prices
More
